Oruka Therapeutics Shares Slide as Fairmount Offloads $300M Stake

Key Facts

In a move reflecting institutional selling pressure within the biotech sector, Oruka Therapeutics shares declined significantly during after-hours trading. This drop followed an SEC filing revealing that Fairmount sold 3.55 million shares of its holding. According to reports, the offloaded stake is valued at approximately $300 million, triggering an immediate negative reaction from market participants.

Large-scale exits by major shareholders often raise concerns regarding current valuations, particularly in the volatile biopharma space. Based on similar sector transactions, a sale of this magnitude creates technical pressure due to the sudden increase in supply, per market data. This move mirrors institutional divestments seen in peer companies over the last quarter as early investors look to crystallize gains following periods of rapid growth.

Traders should monitor technical support levels at the next market open, noting that the stock is trading at depressed levels following the after-hours activity on July 1, 2026. Looking ahead, macro catalysts such as the scheduled speech by Fed Governor Bowman on June 25, 2026, will be critical as investors gauge the broader interest rate environment for growth-oriented biotech firms.